IN THE CLAIMS

Please cancel claims 1-4, which were allowed, as amended, in U.S. Patent Application Serial No. 09/089,373. Please cancel claim 7 without prejudice or disclaimer of the subject matter therein.

Please amend the claims as follows:

5. (Once amended) A pharmaceutical composition which comprises:

(i) an effective amount of a compound [pipecolic acid derivative] for treating alopecia or promoting hair growth in an animal in need thereof, wherein said compound is [the pipecolic acid derivative is a compound] of formula I



I

or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:

A is [CH_2,] O, NH, or N-(C_1-C_4 alkyl);

B and D are independently Ar, C_5-C_7 cycloalkyl substituted C_1-C_6

straight or branched chain alkyl or C_2-C_6 straight or branched chain alkenyl, C_5-C_7 cycloalkenyl substituted C_1-C_6 straight or branched chain alkyl or C_2-C_6 straight or branched chain alkenyl, or Ar substituted C_1-C_6 straight or branched chain alkyl or C_2-C_6 straight or branched chain alkenyl,

wherein in each case, one or two carbon atom(s) of said alkyl or alkenyl [may be] is/are optionally substituted with one or two heteroatom(s) independently selected from the group consisting of oxygen, sulfur, SO, and SO_2 [in chemically reasonable substitution patterns],

or B and D are independently the fragment



wherein Q is hydrogen, C_1-C_6 straight or branched chain alkyl or C_2-C_6 straight or branched chain alkenyl; and

T is Ar or C_5-C_7 cycloalkyl substituted at positions 3 and 4 with substituents independently selected from the group consisting of hydrogen, hydroxy, O-(C_1-C_4 alkyl), O-(C_2-C_4 alkenyl), and carbonyl;

Ar is selected from the group consisting of 1-napthyl, 2-

napthyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl and phenyl, monocyclic and bicyclic heterocyclic ring systems with individual ring sizes being 5 or 6 which [contain] have in either or both rings a total of 1-4 heteroatoms independently selected from oxygen, nitrogen and sulfur, [;]

wherein Ar [contains] has 1-3 substituent(s) independently selected from the group consisting of hydrogen, halo, hydroxy, hydroxymethyl, nitro, CF_3, trifluoromethoxy, C_1-C_6 straight or branched chain alkyl, C_2-C_6 straight or branched chain alkenyl, O-(C_1-C_4 straight or branched chain alkyl), O-(C_2-C_4 straight or branched chain alkenyl), O-benzyl, O-phenyl, amino, 1,2-methylenedioxy, carbonyl, and phenyl;

L is either hydrogen or U; M is either oxygen or CH-U, provided that if L is hydrogen, then M is CH-U, or if M is oxygen then L is U;

U is hydrogen, O-(C_1-C_4 straight or branched chain alkyl), O-(C_2-C_4 straight or branched chain alkenyl), C_1-C_6 straight or branched chain alkyl, C_2-C_6 straight or branched chain alkenyl, C_5-C_7 cycloalkyl, C_5-C_7 cycloalkenyl substituted with C_1-C_4 straight or branched chain alkyl or C_2-C_4 straight or branched chain alkenyl, (C_1-C_4 alkyl or C_2-C_4 alkenyl)-Ar, or Ar;

J is hydrogen, C_1 or C_2 alkyl, or benzyl; K is C_1-C_4 straight

or branched chain alkyl, benzyl or cyclohexylmethyl; or J and K are taken together to form a [5-] 7 membered heterocyclic ring which is substituted with oxygen, sulfur, SO, or SO_2;

[n] m is 0-3; and

said [pipecolic acid derivative] compound has an affinity for FKBP-type immunophilins; [and]

(ii) a second hair revitalizing agent; and

(iii) a pharmaceutically acceptable carrier.

6. (Once amended) A pharmaceutical composition which comprises:

(i) an effective amount of a compound [pipecolic acid derivative] for treating alopecia or promoting hair growth in an animal in need thereof, wherein said compound is [the pipecolic acid derivative is a compound] of formula II



II

or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:

A is O, NH, or N-(C_1-C_4 alkyl);

B is hydrogen, CHL-Ar, C_1-C_6 straight or branched chain alkyl, C_2-C_6 straight or branched chain alkenyl, C_5-C_7 cycloalkyl, C_5-C_7 cycloalkenyl, Ar substituted C_1-C_6 alkyl or C_2-C_6 alkenyl, or



wherein L and Q are independently hydrogen, C_1-C_6 straight or branched chain alkyl, or C_2-C_6 straight or branched chain alkenyl; and

T is Ar or C_5-C_7 cyclohexyl substituted at positions 3 and 4 with substituents independently selected from the group consisting of hydrogen, hydroxy, O-(C_1-C_4 alkyl), O-(C_2-C_4 alkenyl), and carbonyl;

Ar is selected from the group consisting of 1-napthyl, 2-napthyl, 2-furyl, 3-furyl, 2-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl$_\perp$ and phenyl$_\perp$ having 1-3 substituent(s) independently selected from the group consisting of hydrogen, halo, hydroxy, nitro, CF_3, C_1-C_6 straight or branched chain alkyl, C_2-C_6 straight or branched chain alkenyl, O-(C_1-C_4 straight or branched

chain alkyl), O-(C_2-C_4 straight or branched chain alkenyl), O-benzyl, O-phenyl, amino, and phenyl; [.]

D is hydrogen or U; E is oxygen or CH-U, provided that if D is hydrogen, then E is CH-U, or if E is oxygen, then D is U;

U is hydrogen, O-(C_1-C_4 straight or branched chain alkyl), O-(C_2-C_4 straight or branched chain alkenyl), C_1-C_6 straight or branched chain alkyl, C_2-C_6 straight or branched chain alkenyl, C_5-C_7-cycloalkyl, C_5-C_7 cycloalkenyl substituted with C_1-C_4 straight or branched chain alkyl or C_2-C_4 straight or branched chain alkenyl, 2-indolyl, 3-indolyl, (C_1-C_4 alkyl or C_2-C_4 alkenyl)-Ar, or Ar;

J is hydrogen, C_1 or C_2 alkyl, or benzyl; K is C_1-C_4 straight or branched chain alkyl, benzyl or cyclohexylethyl; or J and K are taken together to form a [5-] 7 membered heterocyclic ring which is substituted with oxygen, sulfur, SO, or SO_2; and

said compound has an affinity for FKBP-type immunophilins;

(ii) a second hair revitalizing agent; and

(iii) a pharmaceutically acceptable carrier.

8. (Once amended) A pharmaceutical composition which comprises:

(i) an effective amount of a compound [pipecolic acid derivative] for treating alopecia or promoting hair growth in an animal in need thereof, wherein said

compound is [the pipecolic acid derivative is a compound] of [formula] formula IV



IV

or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:

A3

V is C, N, or S;

J and K, taken together with V and the carbon atom to which they are respectively attached, form a [5-] 7 membered saturated or unsaturated heterocyclic ring [containing] having, in addition to V, one or more heteroatom(s) selected from the group consisting of O, S, SO, SO_2, N, NH, and NR;

R is either C_1-C_9 straight or branched chain alkyl, C_2-C_9 straight or branched chain alkenyl, C_3-C_9 cycloalkyl [cycloakyl], C_5-C_7 cycloalkenyl, or Ar_1,

wherein R is either unsubstituted of substituted with one or more substituent(s) independently selected from the group consisting of halo, haloalkyl, carbonyl, carboxy, hydroxy, nitro, trifluoromethyl, C_1-C_6 straight or

branched chain alkyl, C_2-C_6 straight or branched chain alkenyl, C_1-C_4 alkoxy, C_2-C_4 alkenyloxy, phenoxy, benzyloxy, thioalkyl, alkylthio, sulfhydryl, amino, alkylamino, aminoalkyl, aminocarboxyl, and Ar_2;

Ar_1 and Ar_2 are independently an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring, [;]

wherein the individual ring size is 5-8 members, [;]

wherein said heterocyclic ring has [contains] 1-6 heteroatom(s) independently selected from the group consisting of O, N, and S;

[A, B, D, L, M, and m are as defined in claim 5 above;]

A is O, NH, or N-(C_1-C_4 alkyl);

B and D are independently Ar, C_5-C_7 cycloalkyl substituted C_1-C_6 straight or branched chain alkyl or C_2-C_6 straight or branched chain alkenyl, C_5-C_7 cycloalkenyl substituted C_1-C_6 straight or branched chain alkyl or C_2-C_6 straight or branched chain alkenyl, or Ar substituted C_1-C_6 straight or branched chain alkyl or C_2-C_6 straight or branched chain alkenyl,

wherein in each case, one or two carbon atom(s) of said alkyl or alkenyl is/are optionally substituted with one or two heteroatom(s) independently selected from the group consisting of oxygen, sulfur, SO, and SO_2,

or B and D are independently the fragment



wherein Q is hydrogen, C_1-C_6 straight or branched chain alkyl or C_2-C_6 straight or branched chain alkenyl; and

T is Ar or C_5-C_7 cycloalkyl substituted at positions 3 and 4 with substituents independently selected from the group consisting of hydrogen, hydroxy, O-(C_1-C_4 alkyl), O-(C_2-C_4 alkenyl), and carbonyl;

Ar is selected from the group consisting of 1-napthyl, 2-napthyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, phenyl, and monocyclic and bicyclic heterocyclic ring systems with individual ring sizes being 5 or 6, which have in either or both rings a total of 1-4 heteroatoms independently selected from oxygen, nitrogen and sulfur,

wherein Ar has 1-3 substituent(s) independently selected from the group consisting of hydrogen, halo, hydroxy, hydroxymethyl, nitro, CF_3, trifluoromethoxy, C_1-C_6 straight or branched chain alkyl, C_2-C_6 straight or branched chain alkenyl, O-(C_1-C_4 straight or branched chain alkyl), O-(C_2-C_4 straight or branched chain